- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Allogene Therapeutics announced the activation of clinical trials across the U.S. and Canada, aligning with the FDA on pivotal trial design.
Allogene Therapeutics is seeking designations for its cema-cel therapy and expanding its clinical trials internationally, including the ALPHA3 trial.
1 report, 1 independent
Updated Aug 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Allogene Therapeutics is seeking designations for its cema-cel therapy and expanding its clinical trials internationally, including the ALPHA3 trial.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- A network focused on cell and gene therapies is expanding to include sites in Northern California, involving the CA Institute for Regenerative Medicine and the FDA.
- Allarity Therapeutics has established a facility in Horsholm, Northern Europe, and the FDA requires CLIA certification for biomarker testing.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- Cardiff Oncology and Nerviano Medical Sciences are seeking FDA regulatory review for Phase 3 trials and managing a licensing dispute over onvansertib.